NASDAQ : CCNE
-$0.88 (-2.5%)
| Source | Headline |
|---|---|
|
CNB Financial Corporation Announces Quarterly Dividend for Series A Preferred Stock and Related Depositary Shares Distribution
CLEARFIELD, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) (the "Corporation") has announced the declaration of a quarterly cash dividend of $0.4453125 per depositary share (Nasdaq: CCNEP), resulting from the Corporation's declaration of a quarterly cash dividend of $17.8125 per share on its Series A Preferred Stock. globenewswire.com - 2026-07-14 16:05:00 |
|
HWBK vs. CCNE: Which Community Bank Stock Is the Better Buy?
Hawthorn Bancshares and CNB Financial ride on different growth and diversification drivers, but which looks more compelling now? Let's dive in. zacks.com - 2026-07-14 14:00:39 |
|
CNB Financial (CCNE) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes? zacks.com - 2026-07-10 12:46:13 |
|
Are You Looking for a Top Momentum Pick? Why CNB Financial (CCNE) is a Great Choice
Does CNB Financial (CCNE) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2026-06-18 13:00:34 |
|
Is the Options Market Predicting a Spike in CNB Financial Stock?
Investors need to pay close attention to CCNE stock based on the movements in the options market lately. zacks.com - 2026-06-17 15:56:04 |
|
Why CNB Financial (CCNE) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes? zacks.com - 2026-06-08 12:46:24 |
|
Why CNB Financial (CCNE) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes? zacks.com - 2026-05-22 12:46:20 |
|
CNB (CCNE) Upgraded to Buy: What Does It Mean for the Stock?
CNB (CCNE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2026-05-18 13:01:14 |
|
CNB Financial Corporation Announces Quarterly Dividend For Common Stock
CLEARFIELD, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CNB Financial Corporation (Nasdaq: CCNE) declared a quarterly cash dividend of $0.19 per share of common stock payable on June 15, 2026 to common stock shareholders of record as of June 1, 2026. globenewswire.com - 2026-05-12 16:05:00 |
|
CNB Financial (CCNE) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes? zacks.com - 2026-05-06 12:46:46 |
|
Is the Options Market Predicting a Spike in CNB Financial Stock?
Investors need to pay close attention to CCNE stock based on the movements in the options market lately. zacks.com - 2026-05-05 15:40:18 |
|
CNB Financial (CCNE) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CNB (CCNE) have what it takes? zacks.com - 2026-04-20 12:46:26 |
|
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amplified solid tumors at the American Association for Cancer Research (AACR) Annual Meeting 2026, being held April 17-22 in San Diego, CA. globenewswire.com - 2026-04-20 07:00:00 |